Acasti Granted Composition & Use Patent in China

Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Chinese Patent Office has granted Acasti a composition and use patent (the "Patent").The Patent (ZL 201080059930.4), which is valid until 2030, relates to concentrated therapeutic phospholipid omega-3 compositions and covers methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases, and neurodegenerative diseases. "To date, Acasti has received patents in the United States, Australia, Panama and South Africa for its phospholipid composition," highlighted Benoit Huart, Director Legal Affairs at Acasti. "As well, similar patent applications are pending in more than 40 jurisdictions worldwide and are actively being pursued. This is yet another example of our commitment to build and extend our patent estate.""Today's announcement further enhances the value of our intellectual property, by protecting a vast market and providing potential expansion opportunities for Acasti's products going forward," said Pierre Lemieux, PhD, Acasti's Chief Operating Officer. "There is a large unmet need for high-quality, well-studied and differentiated krill products in China. It is the third largest pharmaceutical market in the world, with an average compound annual sales growth rate of approximately 20% over the past ten years."